International unlicensed name: Ondansetron 

Formulation: solution for injections 2mg/ml – 2ml(4mg)  in ampoules  №5, 4 ml(8mg) in ampoules №5       


Auxiliary reagents: none

Pharmacotherapeutic group: Antiemetic warning the occurrence of nausea

Selective 5-HT3 receptor antagonist. 

Shelf life: 3 years

Storage condition  Store below 30°C. Protect from light.

Certificate of registry number: № UA 13558\01\01

Certificate validity period:  till 09.04.2019  

AO code:    А04А А01

The Ministry of Health of Ukraine Order № 256 from  09.04.2014


  1. Prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin ≥50 mg/m2.
  2. Prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.
  3. Prevention of nausea and vomiting associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen.
  4. Prevention of postoperative nausea and/or vomiting. As with other antiemetics, routine prophylaxis is not recommended for patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. In patients where nausea and/or vomiting must be avoided postoperatively, Ondansetron


  • Hypersensitivity with any of components of the drug
  • Don/t use with  apomorphiny gydrochloridum
  • Pregnancy. Nursing mothers. 

Mechanism of action

Ondansetron Solution blocks the actions of chemicals in the body that can trigger nausea and vomiting.